Description

Ethamsylate Tablets (250 mg / 500 mg)

Healthy Inc is a specialized global supplier and exporter of advanced hemostatic, gynecological, and surgical therapeutics. We provide ultra-high-purity, fast-acting Ethamsylate Tablets (250 mg / 500 mg), manufactured in WHO–GMP certified, high-capacity oral solid dosage facilities. This “Capillary Stabilizing Hemostatic Agent” is a massive-volume, essential export to gynecology centers, surgical wards, emergency departments, and government health ministries in LATAM, the Middle East, Africa, and Southeast Asia, serving as the globally trusted, first-line intervention for the rapid control of capillary hemorrhage and dysfunctional uterine bleeding.

Product Overview

This formulation contains Ethamsylate, a unique synthetic antihemorrhagic and angioprotective agent that fundamentally reduces bleeding time without altering the natural coagulation cascade.

The “Non-Thrombogenic Hemostatic” Specialist:

• Mechanism 1 (Capillary Resistance & Platelet Adhesion): Ethamsylate acts during the very first step of hemostasis (the body’s process to stop bleeding). It rapidly improves the adhesiveness of blood platelets and restores the physical resistance of capillary walls. By doing this, it drastically reduces capillary permeability, physically stopping the leakage of blood from microvessels.
• Mechanism 2 (Prostaglandin Inhibition): It actively inhibits the synthesis and action of prostaglandins (specifically PGI2 and PGE2), which normally cause blood vessels to dilate and increase bleeding. This dual action rapidly normalizes bleeding time in patients experiencing severe capillary hemorrhage.
• The Ultimate Safety Advantage (Zero Clotting Risk): Unlike Tranexamic Acid, which stops the breakdown of clots, Ethamsylate has absolutely no effect on the fibrinolytic system or systemic coagulation factors. It does not cause the blood to unnaturally coagulate in the veins, meaning it carries zero risk of inducing Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or stroke. This makes it incredibly safe for prolonged prophylactic use in outpatient gynecology.

Product Composition & Strength

We supply this product as a Precision-Blended Film-Coated or Uncoated Tablet, packed in highly secure, moisture-resistant Alu-PVC or Alu-Alu blister strips to ensure the rapid dissolution and complete stability of the active ingredient.

*Pack Sizes: 10×10 Blisters (Optimized specifically for acute 5-to-10 day bleeding control regimens).

Technical & Logistics Specifications

Critical data for Pharmaceutical Importers, Hospital Procurement Boards, and Gynecology Distributors.

Manufacturing Authority

Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.

• Rapid Onset Formulation Engineering: In clinical bleeding emergencies, time is the critical factor. Our 500 mg tablets are specifically engineered utilizing advanced superdisintegrants (like Sodium Starch Glycolate) to guarantee ultra-fast disintegration in the gastric fluid. This ensures peak plasma concentrations are achieved swiftly, initiating capillary stabilization and bleeding control within just 1 to 2 hours of oral administration.

Therapeutic Indications (Human Use)

Indicated for the targeted prevention and treatment of capillary hemorrhage:

• Gynecology: Prophylaxis and treatment of menorrhagia (abnormally heavy or prolonged menstrual bleeding), dysfunctional uterine bleeding, and bleeding associated with intrauterine device (IUD) insertion.
• Surgery & Trauma: Prevention and treatment of pre-operative, peri-operative, and post-operative capillary hemorrhage in all fields of surgery (particularly ENT, dentistry, ophthalmology, and plastic surgery).
• Internal Medicine: Management of hematuria (blood in urine), epistaxis (severe nosebleeds), and gingival bleeding.

Dosage & Administration

Recommended Dosage (Strictly as per Physician Guidelines):

• Adults (Acute Menorrhagia): One 500 mg tablet taken 3 to 4 times a day during menstruation. Treatment is usually initiated 5 days before the expected onset of menstruation and continued for 10 days total.
• Adults (Post-Surgical Bleeding): One 500 mg tablet every 4 to 6 hours as long as the risk of bleeding persists.
• Administration (THE MEALTIME RULE): To significantly reduce the risk of gastrointestinal upset and nausea, this medication should be administered with or immediately after meals with a full glass of water.

Safety Warnings (CRITICAL Regulatory & Clinical Data):

• Acute Porphyria Contraindication (CRITICAL): Ethamsylate is strictly contraindicated in patients with a history of acute porphyria, as it may precipitate a severe, life-threatening attack.
• Fever Induction Risk: In rare cases, Ethamsylate can induce a drug-related fever. If a patient develops an unexplained high fever during therapy, the medication must be discontinued immediately.
• Asthma Caution (Sulfite Sensitivity): Some tablet formulations may contain sulfites as antioxidants, which can trigger severe allergic reactions or bronchospasm in susceptible asthmatic patients.
• Renal Impairment: Because the drug is primarily excreted unchanged by the kidneys, the dosing interval must be carefully adjusted or the drug avoided in patients with severe renal failure.

Global Export & Contract Manufacturing Services

Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving the needs of international Pharma Traders, Wholesalers, and Retail Pharmacy Networks. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for Advanced Hemostatic and Gynecological Formulations, allowing brands to launch high-quality generic medicines under their own label. Whether you are looking for a reliable Hospital Tender Supplier for surgical wards in Africa or a B2B Pharma Marketplace partner for Latin America, our logistics network ensures timely delivery. We actively support Pharmaceutical Drop Shipping models and bulk indenting, ensuring that every Generic Medicine Wholesaler receives WHO-GMP certified products at competitive rates.